1. Food and Drug Administration. FDA grants traditional approval to tarlatamab-dlle for extensive-stage small-cell lung cancer. FDA. November 19, 2025. Accessed November 19, 2025.
AbbVie just scored a major regulatory win at home base. The company’s cancer drug Epkinly has been cleared by the U.S. Food ...
The ANDROMEDA trial showed improved MOD-PFS and OS with daratumumab and hyaluronidase plus VCd compared to VCd alone in light ...
The FDA announced accelerated approval of sevabertinib (Hyrnuo) for HER2-positive non-small cell lung cancer (NSCLC).
The Inflation Reduction Act (IRA) of 2022 mandates price negotiations for certain drugs under Medicare, shortening the exclusivity period historically used to recoup research and development ...
Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...
In San Francisco, a growing number of Latinos who work physically demanding jobs are turning to supplements like Artri Ajo ...
The FDA is removing any mention of risks related to breast cancer, heart disease, and dementia on hormone therapy products ...
Novo Nordisk is expected to announce soon whether its blockbuster GLP-1 drug semaglutide can help slow Alzheimer’s disease ...
The FDA is adding a Boxed Warning label to delandistrogene moxeparvovec-rokl, a gene therapy for Duchenne muscular dystrophy, after reports of fatal liver injuries.
For more than 20 years, hormone therapy for menopause has carried a warning label from the Food and Drug Administration ...
Risk of “acute, serious, and life-threatening” heart inflammation is now on the label of Sarepta's gene therapy for Duchenne ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback